Dermatology · Clinical trials

Bullous Pemphigoid Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About bullous pemphigoid — and why its trials are hard

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, predominantly affecting older adults. Autoantibodies against the hemidesmosomal proteins BP180 (collagen XVII) and BP230 trigger complement activation and eosinophil-rich inflammation at the dermoepidermal junction, producing tense blisters, urticarial plaques, and severe itch. Because patients are frequently frail and multimorbid, the disease and its treatments both carry significant risk. Standard of care has long relied on high-potency topical corticosteroids (clobetasol propionate) for localized disease and systemic corticosteroids, often with steroid-sparing immunosuppressants (e.g., doxycycline, azathioprine, mycophenolate, methotrexate) or off-label rituximab and omalizumab, but few therapies were formally FDA-approved for BP. The type 2 inflammatory axis (IL-4/IL-13, IgE, eosinophils) has emerged as a therapeutic target. Dupilumab achieved positive pivotal results in the LIBERTY-BP ADEPT trial and subsequently became FDA-approved for BP in 2025, marking the first targeted biologic approval in this disease. Trials emphasize sustained disease remission off steroids, itch, and disease-severity scoring (BPDAI).

Indication

Bullous Pemphigoid

ICD-10-CM

L12.0 — Bullous pemphigoid

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)	Approved	Setting	Pivotal trial	Primary endpoint	Magnitude of benefit
Dupilumab (Dupixent)	2025	Adults with bullous pemphigoid (first targeted biologic approved for BP)	LIBERTY-BP ADEPT (Phase 2/3, positive results reported 2024)	Sustained disease remission (complete clinical remission while off corticosteroids) at week 36	About 20% of dupilumab patients achieved sustained remission versus roughly 4% on placebo, with significant improvements in itch and BPDAI severity

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in bullous pemphigoid development come from programmes that failed the endpoint that mattered.

Drug / trial	Endpoint outcome	What contributed
Bertilimumab — Early-phase (Phase 2) evaluation in bullous pemphigoid	Did not progress to approval; the anti-eotaxin-1 antibody program in BP was not advanced to successful pivotal development	Limited and inconclusive efficacy data and program discontinuation; single-target eosinophil-chemoattractant blockade was insufficient (details unverified)

Choosing the right endpoint

Primary endpoints that matter in bullous pemphigoid trials

Sustained disease remission off steroids — Complete remission maintained without oral corticosteroids; the primary regulatory endpoint in ADEPT
BPDAI — Bullous Pemphigoid Disease Area Index quantifying blister, erosion, and urticarial/erythema burden
Peak Pruritus NRS — Patient-reported itch severity, a major symptom-driven endpoint given the heavy itch burden
Cumulative corticosteroid exposure — Total steroid dose over the trial, capturing steroid-sparing benefit and safety

How iNGENū runs bullous pemphigoid trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

↳

Planning a bullous pemphigoid trial?
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.

Request a proposal

Frequently asked questions